1. Home
  2. IMOS vs CRVS Comparison

IMOS vs CRVS Comparison

Compare IMOS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IMOS

ChipMOS TECHNOLOGIES INC.

HOLD

Current Price

$48.33

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$12.17

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMOS
CRVS
Founded
1997
2014
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2007
2016

Fundamental Metrics

Financial Performance
Metric
IMOS
CRVS
Price
$48.33
$12.17
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$30.17
AVG Volume (30 Days)
85.2K
1.6M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
1.51%
N/A
EPS Growth
N/A
48.04
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$21.75
N/A
Revenue Next Year
$4.21
N/A
P/E Ratio
$158.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.06
$3.38
52 Week High
$61.27
$26.95

Technical Indicators

Market Signals
Indicator
IMOS
CRVS
Relative Strength Index (RSI) 48.63 36.24
Support Level $32.65 $6.65
Resistance Level $51.08 $19.21
Average True Range (ATR) 1.96 1.04
MACD -0.94 -0.44
Stochastic Oscillator 18.79 13.81

Price Performance

Historical Comparison
IMOS
CRVS

About IMOS ChipMOS TECHNOLOGIES INC.

ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: